Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01836523 · ClinicalTrials.gov registry record · Phase 3
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
A Phase 3 study of Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,398
- Enrollment target
- 20
- Study locations
NCT01836523: Completed Phase 3 study of Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S.
NCT01836523 is a Phase 3 study of Diabetes and Diabetes Mellitus, Type 1 that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,398 participants, below the 3,024-participant average among 338 other Diabetes trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01836523, a Phase 3 study of Diabetes and Diabetes Mellitus, Type 1, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,398 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.
Primary Outcome
Change from baseline in HbA1c at week 52. Missing values were handled by using a mixed model for repeated measurements (MMRM).
Conditions Studied
Interventions
- DRUG placebo
- DRUG liraglutide
Study Locations (20)
California
- Novo Nordisk Investigational Site - Concord
- Novo Nordisk Investigational Site - Encino
- Novo Nordisk Investigational Site - Escondido
- Novo Nordisk Investigational Site - Huntington Beach
- Novo Nordisk Investigational Site - La Mesa
- Novo Nordisk Investigational Site - Lancaster
- Novo Nordisk Investigational Site - Monterey
- Novo Nordisk Investigational Site - San Mateo
- Novo Nordisk Investigational Site - San Ramon
- Novo Nordisk Investigational Site - Walnut Creek
Florida
- Novo Nordisk Investigational Site - Fort Lauderdale
- Novo Nordisk Investigational Site - Hialeah
- Novo Nordisk Investigational Site - Jacksonville
- Novo Nordisk Investigational Site - Tampa
Georgia
- Novo Nordisk Investigational Site - Atlanta
- Novo Nordisk Investigational Site - Atlanta
- Novo Nordisk Investigational Site - Marietta
- Novo Nordisk Investigational Site - Roswell
Arkansas
- Novo Nordisk Investigational Site - Little Rock
Colorado
- Novo Nordisk Investigational Site - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,398 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
What the finished NCT01836523 record still lists
NCT01836523 is an interventional study that assigns participants to a tested intervention. Its 1,398 participants enrollment target places it among the larger protocols in the corpus, below the 3,024-participant average among 338 other Diabetes trials with a reported enrollment target (54% lower).
The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01836523 names 20 study sites across 5 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT01836523 about?
NCT01836523 is a clinical study titled "The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes". This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.
What is the current status of trial NCT01836523?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,398 participants. The study started on 2013-11. Estimated completion is 2015-06.
What conditions does trial NCT01836523 study?
This clinical trial studies the following conditions: Diabetes, Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT01836523?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG).
Who is sponsoring clinical trial NCT01836523?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01836523 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01836523's enrollment target sits among peer trials
1,398 32nd of 338 higher than 307 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial to Assess Chelation Therapy in Critical Limb Ischemia
RECRUITING · Phase 3
-
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes
COMPLETED · Phase 3
-
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
COMPLETED · Phase 3
-
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
COMPLETED · Phase 3
-
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
- NCT04250857 · 1,400 participants
HeartStart FRx Defibrillator Event Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia